Linde plc (EU)

  • WKN: A2DSYC
  • ISIN: IE00BZ12WP82
  • Land: Irland

Nachricht vom 25.03.2019 | 15:55

DGAP-DD: Linde plc english


Linde plc: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

25.03.2019 / 15:54
The issuer is solely responsible for the content of this announcement.


Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them

[This form is required for disclosure of transactions under Article 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)]

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr. Anne K. Roby
2 Reason for the notification
a) Position/status Member of the Management Committee
b) Initial Notification Amendment Initial notification
 
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Linde public limited company
b) LEI 8945002PAZHZLBGKGF02
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument,
type of
instrument
Identification code
Share Options ('Options')
Restricted Stock Units ('RSUs')
Ordinary Shares

International Securities Identification Number (ISIN): IE00BZ12WP82

German Securities Identification Number (Wertpapierkennnummer, WKN): A2D SYC

Ticker Symbol: LIN
b) Nature of the transaction Grant of Options
The grant of 26,230 Options of Linde plc which shall vest over three years in three consecutive equal annual instalments beginning on 20 March 2020.

Grant of RSUs
The grant of 2,330 RSUs of Linde plc which shall vest in full and payout in Linde plc Ordinary Shares on a one-for-one basis on or about 20 March 2022, subject to certain conditions having been fulfilled.

Exercise of options over Ordinary Shares and disposal of Ordinary Shares
The exercise of 13,195 options over Ordinary Shares (expiring on 22 February 2021) at an exercise price of US$97.84 and the subsequent disposal of 3,159 Ordinary Shares at an average per share sale price of US$176.77 per Ordinary Share.
c) Price(s) and volume(s) Price(s) Volume(s)
    Grant of Options
    US$0.00 26,230 Options
    Grant of RSUs
    US$0.00 2,330 RSUs
  Exercise of options and disposal of Ordinary Shares
  Exercise  
US$97.84 13,195 options
Disposal  
US$176.77 (average per share sale price) 3,159 Ordinary Shares
d) Aggregated information Price Aggregated volume
    N/A N/A
       
e) Date of the transaction 20 March 2019
f) Place of the transaction Outside of trading venue (in respect of transactions 1 and 2)
New York Stock Exchange (in respect of transaction 3)
g) Additional Information Grant of Options
Any unexercised Options shall expire on 20 March 2029. The exercise price in respect of each Option is US$176.63.

Exercise of options over Ordinary Shares and disposal of Ordinary Shares
10,036 Ordinary Shares were withheld by Linde plc to cover the exercise price of options over 13,195 Ordinary Shares and taxes (at an average per share sale price of US$176.77 per Ordinary Share). Actual per share sale prices ranged from $176.77 to $176.79.


25.03.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Syzygy AG: EBIT-Prognose überfüllt, weiteres Wachstum in Sicht

Mit einer erneut außerordentlich guten Entwicklung der in Deutschland ansässigen Tochtergesellschaften war der SYZYGY-Konzern in der Lage, die Umsatzbasis auf 65,82 Mio. EUR (VJ: 60,67 Mio. EUR) auszubauen. Das Zuwachs von 8,5 % liegt leicht unter der ursprünglichen Unternehmens-Guidance eines zweistelligen Umsatzwachstums. Die Prognose einer EBIT-Marge im oberen einstelligen Bereich wurde aber voll erfüllt. Auf Basis der erreichten Neukundengewinne prognostiziert das Unternehmensmanagement für 2019 ein Umsatzwachstum in einem hohen einstelligen Prozentbereich. Das EBIT sollte um rund 10 % und damit überproportional ansteigen. Unsere Analysten sind weiter positiv für das Unternehmen mit einem Kursziel von 12,15 EUR je Aktie.

Aktueller Webcast

Celanese Corporation

Q1 2019 Celanese Corp Earnings Conference Call

23. April 2019

Aktuelle Research-Studie

SAF-HOLLAND S.A.

Original-Research: SAF-Holland S.A. (von Montega AG): Kaufen

18. April 2019